Balmoral Australia Pty Ltd is a limited by shares, Australian proprietary company. This corporation was registered on 2001-02-21 and was issued with the 095987367 ACN. Its Australian Business Number is 13095987367. Since 2014-09-21, the company is headquartered in NSW, post code 2064. The previous headquarters were located in NSW 2064 (from 2014-01-13 to 2014-09-21), NSW 2064 (from 2001-03-21 to 2014-01-13). Balmoral Australia Pty Ltd was registered for the GST on 2001-02-21. The company has also used 1 business name, namely Balmoral Australia from 2018-10-18 to 2018-11-19. The above data comes from the ABN database which was updated on 2018-11-19.
| Status | From | To |
|---|---|---|
| Active | Wednesday 21st February 2001 | current |
| Name | From | To |
|---|---|---|
| Balmoral Australia Pty Ltd | Friday 9th September 2005 | current |
| Reline Investments Pty Ltd | Thursday 14th June 2001 | Friday 9th September 2005 |
| Reline Investments Pty Limited | Wednesday 21st March 2001 | Thursday 14th June 2001 |
| Name | From | To |
|---|---|---|
| Balmoral Australia | Thursday 18th October 2018 | Monday 19th November 2018 |
| Location | From | To |
|---|---|---|
| NSW 2064 | Sunday 21st September 2014 | current |
| NSW 2064 | Monday 13th January 2014 | Sunday 21st September 2014 |
| NSW 2064 | Wednesday 21st March 2001 | Monday 13th January 2014 |
| Status | From | To |
|---|---|---|
| Registered | Wednesday 21st February 2001 | current |
Advertisements
General information:
| Patent status: |
Filed The specification prior to acceptance and where the application has not lapsed |
| Patent type: | NPE |
International Patent Classification:
| IPC Mark: | A61K 38/16 |
| Section code: | A - human necessities |
| Class code: | 61 - medical or veterinary science; hygiene |
| Subclass code: | K - preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l) |
| Main group code: | 38 - medicinal preparations containing peptides (peptides containing beta-lactam rings a61k0031000000; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, a61k0031000000; ergoline-based peptides a61k0031480000; containing macromolecular compounds having statistically distributed amino acid units a61k0031740000; medicinal preparations containing antigens or antibodies a61k0039000000; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, a61k0047000000) |
| Subgroup code: | 16 - peptides having more than 20 amino acids; gastrins; somatostatins; melanotropins; derivatives thereof |
IP Australia process information:
| Expiry date: | Tuesday 19th October 2032 |
General information:
| Patent status: |
Sealed What happens 3 months after acceptance, assuming there are no oppositions filed. The Status 'sealed' was replaced with 'granted' with IP reform implementation, but from a systems perspective the two statuses are identical. |
| Patent type: | NPE |
International Patent Classification:
| IPC Mark: | A61K 38/16 |
| Section code: | A - human necessities |
| Class code: | 61 - medical or veterinary science; hygiene |
| Subclass code: | K - preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l) |
| Main group code: | 38 - medicinal preparations containing peptides (peptides containing beta-lactam rings a61k0031000000; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, a61k0031000000; ergoline-based peptides a61k0031480000; containing macromolecular compounds having statistically distributed amino acid units a61k0031740000; medicinal preparations containing antigens or antibodies a61k0039000000; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, a61k0047000000) |
| Subgroup code: | 16 - peptides having more than 20 amino acids; gastrins; somatostatins; melanotropins; derivatives thereof |
IP Australia process information:
| Expiry date: | Monday 23rd June 2031 |
General information:
| Patent status: |
Filed The specification prior to acceptance and where the application has not lapsed |
| Patent type: | NPE |
International Patent Classification:
| IPC Mark: | C07K 14/415 |
| Section code: | C - chemistrymetallurgy |
| Class code: | 7 - organic chemistry |
| Subclass code: | K - peptides (peptides containing -lactam rings c07d; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d; ergot alkaloids of the cyclic peptide type c07d0519020000; genetic engineering processes for obtaining peptides c12n0015000000) |
| Main group code: | 14 - peptides having more than 20 amino acids; gastrins; somatostatins; melanotropins; derivatives thereof |
| Subgroup code: | 415 - from plants |
IP Australia process information:
| Expiry date: | Tuesday 19th October 2032 |
Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2024 (http://data.gov.au, http://acnc.gov.au/ and http://abr.business.gov.au/), ©Intellectual Property Government Open Data 2024, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. Aubiz.net will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.